Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survival analysis after neoadjuvant treatment in resectable pancreatic cancer with risk factors
2024-519633-35-00Phase 4Completed
- Sponsor
- Fundación para la Gestión de la Investigación Biomédica de Cádiz
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of irinotecan, fluorouracil, folinic acid and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fundación para la Gestión de la Investigación Biomédica de Cádiz. Primary endpoint: Overall survival. Started Nov 2024; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acidoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-519633-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519633-35-00.